Drug Combo Shrinks Breast Cancer Metastases in Brain

	Tweet

A combination of a “targeted” therapy and chemotherapy shrank metastatic brain tumors by at least 50 percent in one-fifth of patients with aggressive HER2-positive breast cancer, according to data presented by Dana-Farber Cancer Institute investigators at the San Antonio Breast Cancer Symposium.

Lapatinib (Tykerb) and capecitabine (Xeloda) were paired in an extension of a Phase 2 clinical trial in which lapatinib given alone shrank brain metastases significantly in six percent of 241 patients.

In the extension trial, capecitabine was added to lapatinib in 49 patients whose metastases—cancerous colonies in the brain spread from their primary cancer—had progressed while on treatment. With the combination therapy, brain metastases shrank by 20 percent or more in 18 patients (37 percent) and shrank by at least 50 percent in 10 patients (20 percent), reported Nancy Lin, MD, of Dana-Farber’s Breast Oncology Center.

“Very few medications have shown activity in the treatment of brain metastases, particularly in HER-2-positive metastatic breast cancer patients,” said Lin, who led the study with Eric Winer, MD, director of the Dana-Farber Breast Oncology Center. “Therefore, these data are quite encouraging, and further studies are warranted.”

The data (abstract 6076) will be presented on Sunday, Dec. 16 at 7 a.m. CT.

Lapatinib is an oral small-molecule drug from GlaxoSmithKline that is approved along with capecitabine for treating patients with advanced or metastatic breast cancer whose tumors are driven by the abnormal growth signal, HER-2, and who have already undergone therapy including trastuzumab (Herceptin), a taxane drug, and an anthracycline compound. Lapatinib, like trastuzumab, blocks the HER-2 signal.

Up to one-third of women with advanced, HER-2-positive breast cancer may develop metastases to the brain.

“Although radiation treatment is often effective, as women live longer with metastatic cancer, some develop worsening of brain metastases despite radiation,” said Lin. “Because cancer in the brain can have a major impact on quality of life, it is important to have treatment options to address this problem.”

The study was sponsored in part by GlaxoSmithKline.

Dana-Farber Cancer Institute (www. dana-farber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.

Source: Dana-Farber Cancer Institute

RELATED STORIES:
Walnuts may protect against breast cancer   Genes set scene for metastasis   Breast MRIs delay cancer treatment by weeks -study   Birth size is a marker of susceptibility to breast cancer later in life   Suspicion Lingers Over Bisphenol A and Breast Cancer   Common Genetic Mutation in Breast Cancer May Point to New Treatments for Heart Disease   Scientists Discover New Therapeutic Target for Some Breast Cancers   Mastectomy Mystery: Why It’s a Choice When Cancer Isn’t Evident   Lactate Plays a Role in Breast Cancer Development   MRI finds earlier breast cancers in gene carriers   Gene Variant Increases Breast Cancer Risk   Study identifies potential ‘safe period’ for hormone replacement use   Discovery of protein fragment that helps predict breast cancer outcome   Soy reduces breast cancer risk by receptor status   Acupuncture May Relieve Joint Pain Caused by Some Breast Cancer Treatments   Black women often refuse breast cancer treatment   UBC discovery may lead to ‘smart’ therapies for breast, ovarian cancer   Soy isoflavones may modify risk of breast cancer   Mammogram results often wrong, U.S. study finds   Preschool diet linked to later breast cancer risk   Decline in Breast Cancer Cases Likely Linked to Reduced Use of Hormone Replacement   Interventions for relieving the pain and discomfort of screening mammography

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]